Oppenheimer Asset Management Inc. Has $7.24 Million Stake in Sanofi (NASDAQ:SNY)

Oppenheimer Asset Management Inc. lowered its stake in Sanofi (NASDAQ:SNY) by 7.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 125,595 shares of the company’s stock after selling 10,156 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Sanofi were worth $7,238,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Northwest Investment Counselors LLC acquired a new stake in shares of Sanofi during the 3rd quarter worth approximately $29,000. POM Investment Strategies LLC bought a new stake in shares of Sanofi during the 2nd quarter valued at $25,000. Concord Wealth Partners lifted its stake in shares of Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the period. Arrow Financial Corp bought a new position in shares of Sanofi in the 2nd quarter worth $35,000. Finally, Fortitude Family Office LLC grew its stake in shares of Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares during the period. Institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

Shares of SNY opened at $47.82 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market capitalization of $121.36 billion, a PE ratio of 24.40, a P/E/G ratio of 1.26 and a beta of 0.61. The stock has a 50 day simple moving average of $55.05 and a 200 day simple moving average of $52.23. Sanofi has a 52-week low of $45.13 and a 52-week high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.55 earnings per share. Sell-side analysts predict that Sanofi will post 4.27 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on SNY. Argus raised their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.